



Furocyst[®]

For Management of PCOS

INTRODUCTION

Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders. In young girls, the symptoms are mainly cosmetic as they get disturbed by acne, weight gain and facial hair. In married women, PCOS often manifests as inability to conceive. PCOS affects an estimated 1 in 10 women, which is why National Institutes of Health (NIH) has announced it as a major public-health issue for women.

PCOS is of clinical and public health importance as its prevalence is very high among women of reproductive age.

FUROCYST

Furocyst® is a patented product derived from single herb with a proprietary manufacturing process involving separation of active ingredients without affecting chemical properties of the active fractions.

Furocyst is supported by 2 clinical studies on a total of 150 subjects for management of PCOS and the same have been published in well-known international journals like WJPR, IJMS, FASEBJ and NCBI. It has been proven safe and effective. A further study on 375 PCOS patients titled “Evaluating the Performance of Furocyst in Polycystic Ovary Syndrome Patients”, is underway at the reputed Post Graduate Institute of Medical Education and Research. Furocyst has also been accepted under the Prime Minister’s Fellowship Scheme for Doctoral Research.

Furocyst is touted to improve insulin sensitivity and, in turn, may regulate circulating androgen levels. It is also said to improve insulin-mediated glucose disposal in women with PCOS. Furocyst helped to improve menstrual period in the study subjects and thus, might be regulating effect of insulin on ovarian androgen biosynthesis, theca cell proliferation and endometrial growth. It might be regulating ovarian androgen production leading to disappearance or decrease in size and number of cysts.

EFFICACY CONCLUSIONS BASED ON CLINICAL STUDIES

- It caused significant reduction in the ovary volume.
- 46% of the study population showed reduction in the cyst size.
- 36% of the study population showed complete dissolution of the cysts.
- 12% of the patients got pregnant.
- 71% of the patients reported regular menstrual cycle on completion of the treatment.
- Overall 94% of the patients reported positively or got benefitted from the fenugreek extract dosing.
- Menstrual cycle of the study population was regularized in most of the patients.
- Being a major indicator of insulin resistance, HOMA index also significantly reduced up to 46.54%.

SAFETY CONCLUSION

There was no significant change in Liver Function Test, Renal Function Test, Hemogram and Lipid Profile.

SALIENT FEATURES OF FUROCYST

- ♀ Research-based innovative ingredient
- ♀ Protected by product and process patents
- ♀ stability studies established
- ♀ Water soluble ingredient

Disclaimer - Information provided is for healthcare professionals only & is not for individual use.
The statements made above have not been evaluated by FDA to diagnose, treat, cure or prevent diseases.

www.furocyst.com